An Approved Cancer Drug Becomes the Off-Switch for a New Controllable CAR-T Cell

CAR-T cell therapy has transformed outcomes for patients with certain blood cancers over the past decade. Yet its application remains limited: engineered immune cells have largely failed against solid tumors, and their tendency to attack healthy tissue or trigger systemic immune overreactions can cause serious, sometimes fatal side effects. Controlling CAR-T activity after infusion has become one of the central engineering challenges in the field.

A team at Ludwig Cancer Research Lausanne and the Ecole Polytechnique Federale de Lausanne (EPFL) has now built a CAR-T cell with a clinically accessible off-switch. Their system, described in Nature Chemical Biology, uses venetoclax - a drug already approved by the FDA for treating certain blood cancers - to disengage the engineered immune cells from their targets on demand.

What Makes DROP-CAR Different

Most existing controllable CAR-T approaches work by triggering the destruction of the engineered cells when the switch is activated. That stops the therapy, but it also eliminates the cells permanently, requiring a fresh infusion if treatment needs to resume.

The new system, called DROP-CAR for drug-regulated off-switch PPI CAR, works differently. The switch acts at the outside surface of the cell rather than inside it. Two protein domains hold the CAR together: a computationally designed human domain called dmLD3 binds tightly to a protein called BCL-2. When venetoclax is given, it disrupts that protein-protein interaction (the PPI in the name), causing the two halves of the CAR to separate. The cell detaches from its cancer target. When venetoclax is withdrawn, the domains reassemble and the CAR-T cells resume their activity.

"Our work introduces a simple and clinically realistic way to reversibly dial down CAR-T cell activation using as a remote control a cancer drug that is already in clinical use as a cancer therapy," said Melita Irving, who led the work with Greta Maria Paola Giordano Attianese at Ludwig Lausanne, alongside Leo Scheller and Bruno Correia at EPFL.

The Architecture of a Controllable CAR

A standard CAR-T cell carries an engineered receptor that sticks out of the cell surface, with an antibody-derived end that binds to a cancer antigen and an internal tail that triggers the cell's killing machinery when that antigen is detected. The internal signaling components typically include the CD3-zeta domain (required for T cell activation) and a co-stimulatory domain like CD28 that boosts function and persistence.

In DROP-CAR, the cancer-sensing antibody portion carries at its tail end a segment of the BCL-2 protein, while the signaling component of the CAR inside the cell is linked to a strip of protein carrying the dmLD3 domain at its tip. The spontaneous attraction between dmLD3 and BCL-2 holds the two halves together - until venetoclax, which also binds BCL-2, competitively displaces dmLD3 and causes the structure to fall apart.

"Unlike previous controllable CAR designs, our system uses only human protein components and a clinically approved, non-immunosuppressive drug to directly disrupt tumor cell binding by the CAR-T cells," said Giordano Attianese. "Because the switch acts at the level of cell-cell contact rather than inside the cell, it offers an enhanced safety profile and permits control of the CAR-T cells without requiring their sacrifice."

Addressing T Cell Exhaustion

Beyond immediate safety concerns, the ability to pause CAR-T activity could address a longer-term problem: T cell exhaustion. When T cells are continuously stimulated - particularly in the immunosuppressive environment inside solid tumors - they progressively lose their ability to kill target cells, a state driven by epigenetic and transcriptional changes.

Previous research has shown that giving CAR-T cells structured rest periods between bouts of active tumor targeting can partially reverse the genomic alterations driving exhaustion and restore functional efficacy. A system that can be turned on and off repeatedly is better suited to this strategy than one that requires destroying and re-infusing cells.

Preclinical Results and the Path to Clinical Testing

The current paper reports preclinical evaluation in mouse models of cancer, demonstrating both efficacy - the cells kill tumors when active - and controllability. Mouse models often fail to predict outcomes in human patients, and the translation from preclinical success to clinical benefit has been an ongoing challenge across immunotherapy research.

The critical practical advantage is that venetoclax is already approved, with an established clinical safety profile and known pharmacokinetics. This reduces some of the regulatory hurdles that have slowed previous controllable CAR-T systems that required novel or experimental control drugs. The researchers suggest the DROP-CAR system is therefore better positioned for clinical evaluation than alternatives dependent on unapproved agents.

The work was supported by the Swiss National Science Foundation, the Fondazione Teofilo Rossi di Montelera e di Premuda, the Prostate Cancer Foundation, the Swiss Institute for Experimental Cancer Research, the National Centers of Competence in Research, the European Research Council, the Swiss Cancer League, and other funders.